68 related articles for article (PubMed ID: 16322334)
1. Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.
Bojesen SE; Kjaer SK; Høgdall EV; Thomsen BL; Høgdall CK; Blaakaer J; Tybjaerg-Hansen A; Nordestgaard BG
Endocr Relat Cancer; 2005 Dec; 12(4):945-52. PubMed ID: 16322334
[TBL] [Abstract][Full Text] [Related]
2. Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population.
Tofteng CL; Bach-Mortensen P; Bojesen SE; Tybjaerg-Hansen A; Hyldstrup L; Nordestgaard BG
Pharmacogenet Genomics; 2007 Jan; 17(1):85-91. PubMed ID: 17264806
[TBL] [Abstract][Full Text] [Related]
3. Re: Integrin beta3 Leu33Pro homozygosity and risk of cancer.
Wang-Gohrke S; Chang-Claude J
J Natl Cancer Inst; 2005 May; 97(10):778-9; author reply 779-80. PubMed ID: 15900047
[No Abstract] [Full Text] [Related]
4. Integrin beta3 Leu33Pro homozygosity and risk of cancer.
Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
J Natl Cancer Inst; 2003 Aug; 95(15):1150-7. PubMed ID: 12902444
[TBL] [Abstract][Full Text] [Related]
5. Integrin beta3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control study in Germany.
Wang-Gohrke S; Chang-Claude J
Breast Cancer Res Treat; 2004 Dec; 88(3):231-7. PubMed ID: 15609125
[TBL] [Abstract][Full Text] [Related]
6. Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubinski J; Scott RJ; Hamann U
J Med Genet; 2007 Jun; 44(6):408-11. PubMed ID: 17220212
[TBL] [Abstract][Full Text] [Related]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
8. No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype.
Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
Br J Cancer; 2005 Jul; 93(1):167-71. PubMed ID: 15970922
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study.
Frikke-Schmidt R; Nordestgaard BG; Schnohr P; Tybjaerg-Hansen A
Eur Heart J; 2004 Jun; 25(11):943-51. PubMed ID: 15172466
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
Spillman MA; Schildkraut JM; Halabi S; Moorman P; Calingaert B; Bentley RC; Marks JR; Murphy S; Berchuck A
Gynecol Oncol; 2005 May; 97(2):543-9. PubMed ID: 15863158
[TBL] [Abstract][Full Text] [Related]
12. Anthropometry and the risk of epithelial ovarian cancer.
Greer JB; Modugno F; Ness RB; Allen GO
Cancer; 2006 May; 106(10):2247-57. PubMed ID: 16596653
[TBL] [Abstract][Full Text] [Related]
13. Analgesic drug use and risk of epithelial ovarian cancer.
Hannibal CG; Rossing MA; Wicklund KG; Cushing-Haugen KL
Am J Epidemiol; 2008 Jun; 167(12):1430-7. PubMed ID: 18390840
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk.
Patel AV; Calle EE; Pavluck AL; Feigelson HS; Thun MJ; Rodriguez C
Breast Cancer Res; 2005; 7(6):R1168-73. PubMed ID: 16457697
[TBL] [Abstract][Full Text] [Related]
15. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study.
Balaguer F; Castellví-Bel S; Castells A; Andreu M; Muñoz J; Gisbert JP; Llor X; Jover R; de Cid R; Gonzalo V; Bessa X; Xicola RM; Pons E; Alenda C; Payá A; Piqué JM;
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):379-87. PubMed ID: 17368238
[TBL] [Abstract][Full Text] [Related]
16. Relation of anthropometric measurements to ovarian cancer risk in a population-based case-control study (United States).
Peterson NB; Trentham-Dietz A; Newcomb PA; Chen Z; Gebretsadik T; Hampton JM; Stampfer MJ; Willett WC; Egan KM
Cancer Causes Control; 2006 May; 17(4):459-67. PubMed ID: 16596298
[TBL] [Abstract][Full Text] [Related]
17. Common variants in RB1 gene and risk of invasive ovarian cancer.
Song H; Ramus SJ; Shadforth D; Quaye L; Kjaer SK; Dicioccio RA; Dunning AM; Hogdall E; Hogdall C; Whittemore AS; McGuire V; Lesueur F; Easton DF; Jacobs IJ; Ponder BA; Gayther SA; Pharoah PD
Cancer Res; 2006 Oct; 66(20):10220-6. PubMed ID: 17047088
[TBL] [Abstract][Full Text] [Related]
18. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
[TBL] [Abstract][Full Text] [Related]
19. Plasma androgen concentrations and risk of incident ovarian cancer.
Tworoger SS; Lee IM; Buring JE; Hankinson SE
Am J Epidemiol; 2008 Jan; 167(2):211-8. PubMed ID: 17982156
[TBL] [Abstract][Full Text] [Related]
20. Gynecologic and breast cancers in women after exposure to blue asbestos at Wittenoom.
Reid A; Segal A; Heyworth JS; de Klerk NH; Musk AW
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):140-7. PubMed ID: 19124491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
